Academy Capital Management Makes New $12.91 Million Investment in Zoetis Inc. $ZTS

Academy Capital Management purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 88,216 shares of the company’s stock, valued at approximately $12,908,000. Zoetis makes up approximately 1.8% of Academy Capital Management’s investment portfolio, making the stock its 15th biggest position.

Other institutional investors have also recently made changes to their positions in the company. Halbert Hargrove Global Advisors LLC increased its holdings in shares of Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares during the last quarter. KERR FINANCIAL PLANNING Corp purchased a new stake in Zoetis during the third quarter worth approximately $31,000. Financial Consulate Inc. acquired a new position in Zoetis in the third quarter valued at approximately $39,000. SJS Investment Consulting Inc. increased its stake in Zoetis by 1,606.3% in the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after purchasing an additional 257 shares during the last quarter. Finally, TruNorth Capital Management LLC purchased a new position in Zoetis in the third quarter valued at approximately $42,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 3.5%

ZTS stock opened at $117.42 on Thursday. The company has a market cap of $49.57 billion, a price-to-earnings ratio of 19.50, a price-to-earnings-growth ratio of 1.86 and a beta of 0.95. The company has a fifty day moving average price of $124.80 and a 200 day moving average price of $130.99. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. Zoetis Inc. has a 12 month low of $114.47 and a 12 month high of $172.23.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same period in the previous year, the business posted $1.40 earnings per share. Zoetis’s quarterly revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ZTS. UBS Group set a $136.00 price objective on shares of Zoetis in a research report on Thursday, January 29th. Piper Sandler reiterated a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Weiss Ratings raised shares of Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, March 12th. HSBC set a $140.00 price objective on shares of Zoetis in a research note on Wednesday, December 10th. Finally, Barclays started coverage on Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 target price for the company. Six investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.